Agree there are caveats and they have to prove the AAG biomarker response correlation in a prospective fashion and of course no guarantees of that. But, I am also hopeful that ARRY won't really need the AAG biomarker for 520 for success since high AAG levels only occur in 20-30% of MM patients anyways and response so far seems like it may be good enough when including these patients anyways. But, could be a nice bonus if the biomarker does pan out as I'd like to see combo data for 520+kyprolis in low AAG patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.